Why Merrimack Pharmaceuticals Inc. Shares Plunged in After Hours

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Merrimack Pharmaceuticals (NASDAQ: MACK  ) , a biopharmaceutical company focused on developing therapies designed to treat cancer, dipped as much as 15% in after-hours trading after announcing an agreement with Sanofi (NYSE: SNY  ) to regain the worldwide rights to investigational cancer drug MM-121.

So what: According to its after-market press release, Merrimack appears positive after regaining development and worldwide commercialization rights to MM-121 which was tested in a series of phase 2 studies to assess the role of ErbB3 in a multitude of metastatic and neoadjuvant cancer settings. Per its press release, Sanofi will continue to fund existing phase 2 studies for the next six months.

In addition, Merrimack announced data from its second cohort of patients in its midstage collaboration of MM-121 in combination with paclitaxel in triple-negative breast cancer (TNBC) patients. According to its data release, the MM-121 intent to treat arm delivered a pCR rate of 42.9% compared to 51.7% for the control arm. In addition, adverse events were nearly double in the MM-121 arm relative to the control group (28.1% vs. 15.6%), so these results weren't very encouraging.

Now what: The real downside here is Sanofi walking away. By cutting its losses Sanofi walking could signify that there's little value in developing MM-121. More importantly, Merrimack is now down a very knowledgeable and experienced marketing partner and will soon be on the line for all additional MM-121 development costs.

There's also MM-121 itself, which showed no statistical benefit in a midstage treatment-resistant or refractory-advanced ovarian cancer study released in October. As a whole, the hazard ratio of 1 implied no clinical benefit, although it did identify some submarkers which could imply MM-121's future success on a more select group of cancer patients. Today's data from the TNBC cohort adds further fuel to the fire that MM-121 may not target a large enough audience to eventually be worthwhile for Merrimack or investors to stick around. It remains to be seen what Merrimack does moving forward, but as of now I'm sticking squarely on the sidelines.

Merrimack may offer plenty of potential, but keeping up with this top stock over the long haul might prove impossible!
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3001418, ~/Articles/ArticleHandler.aspx, 9/1/2015 4:46:17 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated Moments ago Sponsored by:
DOW 16,058.35 -469.68 -2.84%
S&P 500 1,913.85 -58.33 -2.96%
NASD 4,636.11 -140.40 -2.94%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/1/2015 4:00 PM
MACK $9.53 Down -0.56 -5.55%
Merrimack Pharmace… CAPS Rating: ***
SNY $48.11 Down -0.81 -1.66%
Sanofi (ADR) CAPS Rating: *****